Aug 31, 2022 / 06:30AM GMT
Hans Peter Bohn - PCI Biotech Holding ASA - Independent Chairman
Second quarter presentation. I'm Hans Peter Bøhn, I'm the Chairman of the Board. And with me here today, I have Ronny Skuggedal, our CEO; and I have Morten Luhr, our Strategic Alliance Manager and Business Development Manager.
2022, to say the least, has been a difficult year for PCI Biotech. At the beginning of the year, we were forced to abandon our lead project with fimaChem in bile duct cancer, as you know. And later now, we discovered that -- we found that there was not sufficient interest among our shareholders and the finance community to finance our backup project with fimaVACC in head and neck cancer.
As a result, we were -- or we decided to close down and wind down the part of the company that is capable of running clinical trials. As a result, we now have an organization -- or we will get an organization with approximately half the number of employees as we had at the beginning of the year. Needless to say, this has been difficult for employees as well as for shareholders as well and also our partners and
Q2 2022 PCI Biotech Holding ASA Earnings Call Transcript
Aug 31, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers